Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (9781)	12/17/2003 1:55:03 PM
From: Biomaven	Respond to of 52153

There are intractable ethical issues surrounding clinical trials. As a good example, there was grumbling by some doctors when the recent breast cancer trials of aromatase inhibitors were stopped early when the drug group did better. The issue was that by stopping the trial early they will lose valuable information about longer-term use that will impact the treatment of future patients. The ultimate horror story was bone-marrow transplants in breast cancer. It took many years for trials to finally show that this was a bad idea, partly because nobody wanted to participate in a randomized trial. Peter